Spero Therapeutics (SPRO) Retained Earnings (2016 - 2026)

Spero Therapeutics (SPRO) has reported Retained Earnings for 11 consecutive years, with -$467.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 1.55% year-over-year to -$467.8 million; the trailing twelve-month figure through Jun 2026 stood at -$467.8 million (up 1.55% YoY), and the FY2025 full-year result was -$451.1 million, up 1.86% from the prior year.
• Retained Earnings fell to -$467.8 million in Q2 2026 per SPRO's latest filing, from -$458.3 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$391.1 million in Q4 2023 and bottomed at -$482.6 million in Q3 2025.
• Historically, Retained Earnings has averaged -$439.8 million across 5 years, with a median of -$439.9 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings sank 35.89% in 2022, then grew 5.51% in 2023.
• Over 5 years, Retained Earnings stood at -$413.9 million in 2022, then advanced by 5.51% to -$391.1 million in 2023, then slipped by 17.53% to -$459.6 million in 2024, then rose by 1.86% to -$451.1 million in 2025, then retreated by 3.71% to -$467.8 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$467.8 million, -$458.3 million, and -$451.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.